Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells.

Reed S, Li H, Li C, Lin J.

Biochem Biophys Res Commun. 2011 Apr 15;407(3):450-5. doi: 10.1016/j.bbrc.2011.03.014. Epub 2011 Mar 21.

PMID:
21397587
2.

Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells.

Liu A, Liu Y, Xu Z, Yu W, Wang H, Li C, Lin J.

Cancer Sci. 2011 Jul;102(7):1381-7. doi: 10.1111/j.1349-7006.2011.01932.x. Epub 2011 May 5.

3.

Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.

Wei CC, Ball S, Lin L, Liu A, Fuchs JR, Li PK, Li C, Lin J.

Int J Oncol. 2011 Jan;38(1):279-85.

PMID:
21109950
4.

A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.

Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, Lin J.

Neoplasia. 2010 Jan;12(1):39-50.

5.

Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib.

Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH.

Blood. 2005 Dec 15;106(13):4330-8. Epub 2005 Aug 25.

6.

Anticancer effects of celecoxib through inhibiton of STAT3 phosphorylation and AKT phosphorylation in nasopharyngeal carcinoma cell lines.

Liu DB, Long GX, Mei Q, Wang JF, Hu GY, Gan L, Li WW, Sun W, Liu SF, Jiang JZ, Hu GQ.

Pharmazie. 2014 May;69(5):358-61.

PMID:
24855827
7.

Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells.

Yang MY, Lee HT, Chen CM, Shen CC, Ma HI.

Int J Mol Sci. 2014 Jun 18;15(6):11013-29. doi: 10.3390/ijms150611013.

8.

Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.

Liu Y, Liu A, Li H, Li C, Lin J.

Cancer Prev Res (Phila). 2011 Aug;4(8):1296-305. doi: 10.1158/1940-6207.CAPR-10-0317. Epub 2011 Apr 13.

9.
10.

Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.

Scheper MA, Nikitakis NG, Sauk JJ.

Int J Oral Maxillofac Surg. 2007 Jul;36(7):632-9. Epub 2007 Jun 12.

PMID:
17566705
11.

Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.

Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S.

Clin Cancer Res. 2005 Nov 1;11(21):7674-82.

12.

A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells.

Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C, Houghton PJ, Lin J.

J Biol Chem. 2015 Feb 6;290(6):3418-29. doi: 10.1074/jbc.M114.616748. Epub 2014 Oct 13.

13.

Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.

Liu DB, Hu GY, Long GX, Qiu H, Mei Q, Hu GQ.

Acta Pharmacol Sin. 2012 May;33(5):682-90. doi: 10.1038/aps.2012.18. Epub 2012 Apr 16. Erratum in: Acta Pharmacol Sin. 2013 Apr;34(4):581.

14.

Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells.

Hsiao PW, Chang CC, Liu HF, Tsai CM, Chiu TH, Chao JI.

Toxicol Appl Pharmacol. 2007 Jul 1;222(1):97-104. Epub 2007 Apr 27.

PMID:
17540426
15.
16.

XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells.

Liu Y, Liu A, Xu Z, Yu W, Wang H, Li C, Lin J.

Apoptosis. 2011 May;16(5):502-10. doi: 10.1007/s10495-011-0578-0.

PMID:
21311975
17.
18.

Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.

Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, Termuhlen A, Gross T, Lin J.

Invest New Drugs. 2012 Jun;30(3):916-26. doi: 10.1007/s10637-011-9645-1. Epub 2011 Feb 22.

PMID:
21340507
19.

Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.

Park SW, Kim HS, Hah JW, Jeong WJ, Kim KH, Sung MW.

Anticancer Drugs. 2010 Oct;21(9):823-30. doi: 10.1097/CAD.0b013e32833dada8.

PMID:
20717005
20.

OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.

Zhang S, Suvannasankha A, Crean CD, White VL, Johnson A, Chen CS, Farag SS.

Clin Cancer Res. 2007 Aug 15;13(16):4750-8.

Supplemental Content

Support Center